Fangzhou Inc
Fangzhou Inc operates in the drug retailing segment of the consumer non-cyclicals sector, generating revenue primarily through the sale of pharmaceuticals and related products.
Business. Fangzhou Inc (6086.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Fangzhou Inc (6086.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Fangzhou Inc maintains a strong liquidity position with cash and equivalents amounting to CNY 233.49 million, which is 35.3% of total assets. The company's liquidity FPT (Fundamental Price-to-Tangible Book) is 8.02, indicating a premium valuation relative to its tangible book value. The current ratio of 1.2 suggests the company can cover its short-term liabilities with its current assets, though not with a large margin of safety.
Profitability metrics show a return on equity (ROE) of 7.7%, which is modest but positive, and a return on assets (ROA) of 1.45%, indicating that the company is generating relatively low returns on its asset base. The gross profit margin is 15.87%, and the operating margin is 0.38%, both of which are below the industry median for drug retailers, suggesting potential inefficiencies in cost management or pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution.
Fangzhou Inc's revenue growth trajectory is not clearly defined in the provided data, as historical revenue figures are not available. However, the company's current revenue of CNY 3.53 billion suggests a stable base, and the outlook for the current fiscal year is neutral with no significant growth or contraction expected. The next fiscal year is also projected to remain stable, with no material changes in revenue anticipated.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.23 suggests a conservative capital structure, and the company has not issued additional shares recently. The absence of dilution potential and manageable debt levels contribute to a stable financial profile.
Recent events and filings do not show any material changes or significant corporate actions that would impact the company's financial position. The company's financial statements and disclosures are consistent with a stable and transparent business model, with no notable risks or opportunities highlighted in the latest filings.
- Fangzhou Inc has a strong liquidity position with a current ratio of 1.2 and significant cash reserves.
- The company's profitability is modest, with a ROE of 7.7% and a ROA of 1.45%.
- Revenue is concentrated in a single business segment, increasing exposure to regional and regulatory risks.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.23.
- No immediate liquidity or dilution risks are detected, and the financial profile is stable.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Fangzhou Inc Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Haijiao WangChief Executive Officer, Executive Director